Verona Pharma plc
("Verona Pharma" or the "Company")
Result of AGM
12 April 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all resolutions proposed at the Annual General Meeting (AGM) held today were duly passed.
- End -
For further information, please contact:
|
Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
|
Jan-Anders Karlsson, Chief Executive Officer |
info@veronapharma.com |
|
|
|
|
N+1 Singer (Nominated Adviser and UK Broker) |
Tel: +44 (0)20 7496 3000 |
|
Aubrey Powell / James White |
|
|
|
|
|
FTI Consulting (UK Media and Investor enquiries) |
Tel: +44 (0)20 3727 1000 |
|
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins |
veronapharma@fticonsulting.com |
|
|
|
|
ICR, Inc. (US Media and Investor enquiries) |
|
|
James Heins |
Tel: +1 203-682-8251 |
|
Stephanie Carrington |
Tel. +1 646-277-1282 Stephanie.Carrington@icrinc.com
|
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti‑inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.